These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 10363992)

  • 1. Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas.
    Ingvarsson S; Agnarsson BA; Sigbjornsdottir BI; Kononen J; Kallioniemi OP; Barkardottir RB; Kovatich AJ; Schwarting R; Hauck WW; Huebner K; McCue PA
    Cancer Res; 1999 Jun; 59(11):2682-9. PubMed ID: 10363992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
    Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
    Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands.
    Ahmadian M; Wistuba II; Fong KM; Behrens C; Kodagoda DR; Saboorian MH; Shay J; Tomlinson GE; Blum J; Minna JD; Gazdar AF
    Cancer Res; 1997 Sep; 57(17):3664-8. PubMed ID: 9288768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Fragile Histidine Triad gene and breast cancer.
    Yang Q; Yoshimura G; Sakurai T; Kakudo K
    Med Sci Monit; 2002 Jul; 8(7):RA140-4. PubMed ID: 12118213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations of the FHIT gene in breast cancer: association with tumor progression and patient survival.
    Ingvarsson S; Sigbjornsdottir BI; Huiping C; Jonasson JG; Agnarsson BA
    Cancer Detect Prev; 2001; 25(3):292-8. PubMed ID: 11425271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers.
    Turner BC; Ottey M; Zimonjic DB; Potoczek M; Hauck WW; Pequignot E; Keck-Waggoner CL; Sevignani C; Aldaz CM; McCue PA; Palazzo J; Huebner K; Popescu NC
    Cancer Res; 2002 Jul; 62(14):4054-60. PubMed ID: 12124341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Loss of heterozygosity on chromosome 3p in breast cancer and precancerous lesion].
    Tang XL; Yao GY; Chen LR; Yang ZR; Li SL
    Zhonghua Wai Ke Za Zhi; 2006 Oct; 44(19):1314-7. PubMed ID: 17217815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High incidence of loss of heterozygosity in breast tumors from carriers of the BRCA2 999del5 mutation.
    Ingvarsson S; Geirsdottir EK; Johannesdottir G; Sigbjörnsdóttir BI; Eiriksdottir G; Ragnarsson G; Agnarsson BA; Gudmundsson J; Jonasson JG; Sigurdsson A; Egilsson V; Barkardottir RB
    Cancer Res; 1998 Oct; 58(19):4421-5. PubMed ID: 9766673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma.
    Guler G; Uner A; Guler N; Han SY; Iliopoulos D; Hauck WW; McCue P; Huebner K
    Cancer; 2004 Apr; 100(8):1605-14. PubMed ID: 15073846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
    Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
    Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer.
    Burke L; Khan MA; Freedman AN; Gemma A; Rusin M; Guinee DG; Bennett WP; Caporaso NE; Fleming MV; Travis WD; Colby TV; Trastek V; Pairolero PC; Tazelaar HD; Midthun DE; Liotta LA; Harris CC
    Cancer Res; 1998 Jun; 58(12):2533-6. PubMed ID: 9635574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic FHIT analysis in RER+ and RER- adenocarcinomas of the pancreas.
    Hilgers W; Groot Koerkamp B; Geradts J; Tang DJ; Yeo CJ; Hruban RH; Kern SE
    Genes Chromosomes Cancer; 2000 Mar; 27(3):239-43. PubMed ID: 10679912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FHIT gene and flanking region on chromosome 3p are subjected to extensive allelic loss in Egyptian breast cancer patients.
    Ismail HM; Medhat AM; Karim AM; Zakhary NI
    Mol Carcinog; 2011 Aug; 50(8):625-34. PubMed ID: 21557333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of heterozygosity on chromosomes 3, 9, 13, and 17, including the retinoblastoma locus, in uveal melanoma.
    Scholes AG; Liloglou T; Maloney P; Hagan S; Nunn J; Hiscott P; Damato BE; Grierson I; Field JK
    Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2472-7. PubMed ID: 11581185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent FHIT gene loss of heterozygosity in human papillomavirus-infected non-smoking female lung cancer in Taiwan.
    Wang J; Cheng YW; Wu DW; Chen JT; Chen CY; Chou MC; Lee H
    Cancer Lett; 2006 Apr; 235(1):18-25. PubMed ID: 15935551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Allelic loss and down-regulation of FHIT gene expression in esophageal squamous cell carcinoma].
    Liu FX; Huang XP; Zhao CX; Xu X; Han YL; Cai Y; Wu RL; Wu M; Zhan QM; Wang MR
    Ai Zheng; 2004 Sep; 23(9):992-8. PubMed ID: 15363189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological significance of fragile histidine triad transcription protein expression in breast carcinoma.
    Yang Q; Yoshimura G; Suzuma T; Tamaki T; Umemura T; Nakamura M; Nakamura Y; Wang X; Mori I; Sakurai T; Kakudo K
    Clin Cancer Res; 2001 Dec; 7(12):3869-73. PubMed ID: 11751477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA2 mutations in primary breast and ovarian cancers.
    Lancaster JM; Wooster R; Mangion J; Phelan CM; Cochran C; Gumbs C; Seal S; Barfoot R; Collins N; Bignell G; Patel S; Hamoudi R; Larsson C; Wiseman RW; Berchuck A; Iglehart JD; Marks JR; Ashworth A; Stratton MR; Futreal PA
    Nat Genet; 1996 Jun; 13(2):238-40. PubMed ID: 8640235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of FHIT function in lung cancer and preinvasive bronchial lesions.
    Sozzi G; Pastorino U; Moiraghi L; Tagliabue E; Pezzella F; Ghirelli C; Tornielli S; Sard L; Huebner K; Pierotti MA; Croce CM; Pilotti S
    Cancer Res; 1998 Nov; 58(22):5032-7. PubMed ID: 9823304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos.
    Nelson HH; Wiencke JK; Gunn L; Wain JC; Christiani DC; Kelsey KT
    Cancer Res; 1998 May; 58(9):1804-7. PubMed ID: 9581816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.